Who
Blake Borgeson
Director
Company insider
Files Form 4 as: Director, Recursion Pharmaceuticals.
In numbers
- Trades disclosed
- 112
- Buys
- 0
- Sells
- 67
- Bought
- $0
- Sold
- $13.8M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 15 Apr 2021
- Last trade
- 6 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 7 Oct 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $242K50,000 at $4.84 | filing |
| 1 Sep 2026filed 2 Sep 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $100K30,000 at $3.34 | filing |
| 1 Sep 2026filed 2 Sep 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $100K30,000 at $3.34 | filing |
| 4 Aug 2026filed 6 Aug 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $98K30,000 at $3.25 | filing |
| 4 Aug 2026filed 6 Aug 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $98K30,000 at $3.25 | filing |
| 7 Jul 2026filed 9 Jul 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $159K40,000 at $3.96 | filing |
| 7 Jul 2026filed 9 Jul 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $158K40,000 at $3.96 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —88,424 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $110K30,000 at $3.68 | filing |
| 2 Jun 2026filed 4 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $110K30,000 at $3.68 | filing |
| 5 May 2026filed 7 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $106K30,000 at $3.52 | filing |
| 5 May 2026filed 7 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $106K30,000 at $3.52 | filing |
| 7 Apr 2026filed 8 Apr 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $93K30,000 at $3.10 | filing |
| 7 Apr 2026filed 8 Apr 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $93K30,000 at $3.10 | filing |
| 3 Mar 2026filed 4 Mar 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $588K170,000 at $3.46 | filing |
| 3 Mar 2026filed 4 Mar 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $588K170,000 at $3.46 | filing |
| 3 Feb 2026filed 6 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $924K220,000 at $4.20 | filing |
| 3 Feb 2026filed 6 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $924K220,000 at $4.20 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $959K220,000 at $4.36 | filing |
News
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Lifted to "Sell" by Wall Street ZenRXRX · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Blake Borgeson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.